Karyopharm announces presentation of updated phase 1 selinexor data in patients with treatment-naÏve myelofibrosis at aacr 2023

–  at week 24, 60mg of selinexor in combination with ruxolitinib achieved: 92% svr35 and 78% tss50 in efficacy evaluable population, 79% svr35 and 58% tss50 in intent to treat population – – rapid, deep, sustained spleen response across all subgroups, robust symptom improvement with a generally tolerable and manageable side effect profile; 60mg selinexor is the recommended dose in combination with ruxolitinib – – planning to initiate pivotal phase 3 study in front-line myelofibrosis in 1h 2023 – – company to host investor webcast with key opinion leader dr. john mascarenhas, professor of medicine at the icahn school of medicine at mount sinai, today at 4:30 p.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking